Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Efficacy of intravitreal injection of dexamethasone implant (Ozurdex) in patient with macular edema after retinal vein occlusion

Poster Details

First Author: O. Tumanova RUSSIAN FEDERATION

Co Author(s):    I. Medvedev   N. Dergacheva                 

Abstract Details


To study morphological and functional characteristics of an eye in patients with macular edema developed after a central vein (CRVO) and/or vein branch (BRVO) occlusion after intravitreal dexamethasone implant (Ozurdex) injection.


Medvedev I.,MD, Tumanova O. MD, Dergacheva N, International Eye Care Center, Moscow, Russia


There were 9 patients (9 eyes) in to the analysis. The mean age was 65,8 years. Dexamethasone implant (Ozurdex) was applied by standard method on an ambulatory basis. The average period before the implantation lasted 1  month; an average follow-up -3,0 month.


Efficiency of treatment was evaluated according to the dynamics of retinal thickness by optical coherence tomography and best-corrected visual acuity. The average retinal thickness before implantation- 464microns, after 1 month - 309microns, 2 month- 330microns, 3 month-403microns, 6 month-460microns. Visual acuity before implantation- 20/63, after 1 month-20/140, 2 month-20/140; 3 month-20/100. IOP- before implantation-15,4 mm.m.c, after 1month-19,7; 2 month-19,3; 3 month-17,5.


Dexamethasone implant is an effective method of treatment of macular edema developed as a result of the CRVO/BRVO, but stable effect persists for 2-3 months.

Financial Disclosure:


Back to Poster listing